tiprankstipranks
Advertisement
Advertisement

ADAG Stock Latest News

Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026
Company AnnouncementsAdagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026
5d ago
6K
ADAG
Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints
PremiumRatings
Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints
3M ago
ADAG
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
PremiumCompany Announcements
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
3M ago
6K
ADAG
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
PremiumThe Fly
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
3M ago
ADAG
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
PremiumRatings
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
3M ago
ADAG
Adagene price target raised to $10 from $9 at Guggenheim
PremiumThe FlyAdagene price target raised to $10 from $9 at Guggenheim
3M ago
ADAG
Adagene 18.666M share Spot Secondary priced at $3.75
Premium
The Fly
Adagene 18.666M share Spot Secondary priced at $3.75
3M ago
ADAG
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
Premium
The Fly
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
3M ago
ADAG
Adagene announces results from the latest data cut of muzastotug study
PremiumThe Fly
Adagene announces results from the latest data cut of muzastotug study
3M ago
MRK
ADAG
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
PremiumCompany Announcements
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
3M ago
6K
ADAG
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline
PremiumCompany Announcements
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline
3M ago
6K
ADAG
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028
PremiumCompany Announcements
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028
3M ago
6K
ADAG
Adagene reports FY25 EPS (24c) vs (51c) last year
PremiumThe FlyAdagene reports FY25 EPS (24c) vs (51c) last year
3M ago
ADAG
Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating
Premium
Ratings
Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating
5M ago
ADAG
Adagene Outlines 2026 Clinical Milestones and Reports $74.5 Million Year-End Cash Runway
Premium
Company Announcements
Adagene Outlines 2026 Clinical Milestones and Reports $74.5 Million Year-End Cash Runway
6M ago
6K
ADAG
Adagene provides objective for 2026
PremiumThe Fly
Adagene provides objective for 2026
6M ago
ADAG
Adagene announces FDA fast track designation for muzastotug
PremiumThe Fly
Adagene announces FDA fast track designation for muzastotug
7M ago
MRK
ADAG
Adagene initiated with a Buy at Guggenheim on muzastotug potential
PremiumThe Fly
Adagene initiated with a Buy at Guggenheim on muzastotug potential
8M ago
ADAG
Adagene initiated with a Buy at Guggenheim
PremiumThe Fly
Adagene initiated with a Buy at Guggenheim
8M ago
ADAG
Adagene initiated with an Outperform at LifeSci Capital
PremiumThe FlyAdagene initiated with an Outperform at LifeSci Capital
8M ago
ADAG
Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development
Premium
Company Announcements
Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development
8M ago
6K
ADAG
Adagene announces licensing agreement with Third Arc Bio
Premium
The Fly
Adagene announces licensing agreement with Third Arc Bio
8M ago
ADAG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >